A distinct study in EGFR mutant lung cancer cell lines demonstrated that EGFR-specific TKIs engage a positive feedback loop involving induction of FGFRs and IL6, leading to STAT3 activation to promote cell survival and limit overall drug-induced growth inhibition [35]. Here, EGFR is linked to lung carcinoma.